Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) Obtains Drug Registration Certificate for Crizotinib Capsules

Stock News2025-10-20

Zhito Finance App reported that Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced it has received a drug registration certificate for its product, Crizotinib Capsules, approved by the National Medical Products Administration. Crizotinib Capsules have been available in the Chinese market since 2013 and were included in the medical insurance system in 2018, boasting over ten years of clinical application experience. This medication is primarily used in clinical settings for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK), as well as for advanced non-small cell lung cancer (NSCLC) patients who are positive for ROS1.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1111974886?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111974886","market":"sh","top_or_hot":-1,"title":"Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) Obtains Drug Registration Certificate for Crizotinib Capsules","media":"Stock News","content":"<p>Zhito Finance App reported that Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced it has received a drug registration certificate for its product, Crizotinib Capsules, approved by the National Medical Products Administration. Crizotinib Capsules have been available in the Chinese market since 2013 and were included in the medical insurance system in 2018, boasting over ten years of clinical application experience. This medication is primarily used in clinical settings for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK), as well as for advanced non-small cell lung cancer (NSCLC) patients who are positive for ROS1.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) Obtains Drug Registration Certificate for Crizotinib Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) Obtains Drug Registration Certificate for Crizotinib Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-20 17:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhito Finance App reported that Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced it has received a drug registration certificate for its product, Crizotinib Capsules, approved by the National Medical Products Administration. Crizotinib Capsules have been available in the Chinese market since 2013 and were included in the medical insurance system in 2018, boasting over ten years of clinical application experience. This medication is primarily used in clinical settings for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK), as well as for advanced non-small cell lung cancer (NSCLC) patients who are positive for ROS1.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002907","symbol_name":"华森制药","start_time":0,"source_url":"","article_id":"1111974886","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111974886","pubTimestamp":1760953463,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhito Finance App reported that Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced it has received a drug registration certificate for its product, Crizotinib Capsules, approved by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002907":"华森制药","BK0239":"医药制造"},"translate_title":"重庆法森药业有限公司。（002907.SZ）克唑替尼胶囊获得药品注册证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002907":1},"content_text":"Zhito Finance App reported that Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced it has received a drug registration certificate for its product, Crizotinib Capsules, approved by the National Medical Products Administration. Crizotinib Capsules have been available in the Chinese market since 2013 and were included in the medical insurance system in 2018, boasting over ten years of clinical application experience. This medication is primarily used in clinical settings for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK), as well as for advanced non-small cell lung cancer (NSCLC) patients who are positive for ROS1.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1111974886","isCrawlerRequest":true}